课题基金 / 基金详情

Role for Dipeptidyl Peptidase-IV in the Innate Immune Response

Role for Dipeptidyl Peptidase-IV in the Innate Immune Response
二肽基肽酶-IV 在先天免疫反应中的作用
批准号:
nhmrc : 1016662
负责人:
Dr Roger Yazbek
金额:
$20.15万
依托单位国家:
澳大利亚
项目类别:
Early Career Fellowships
财政年份:
2011
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2011-01-01 至 2014-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
先天免疫系统是bodyÍs抵御入侵生物感染的第一道防线。不适当的先天免疫反应可导致几种炎症性疾病的发展,如炎症性肠病。在IBD儿童中发现了先天免疫反应异常。该项目将确定一种称为DPIV的独特酶在先天免疫反应发展中的作用及其作为IBD治疗靶点的潜力。
英文摘要
The innate immune system is the bodyÍs first line of defence in fighting off infections by invading organisms. An inappropriate innate immune response can lead to the development of several inflammatory conditions such as inflammatory bowel disease. A malfunctioning innate immune response has been identified in children with IBD. This project will determine the role of a unique enzyme called DPIV in the development of innate immune responses and its potential as a therapeutic target for IBD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金